Showing 1901-1910 of 2814 results for "".
- Solta Rolls Out Next Generation Clear + Brilliant Laserhttps://modernaesthetics.com/news/solta-rolls-out-next-generation-clear-brilliant-laser/2473069/Solta Medical is launching Clear + Brilliant Touch laser, the company’s next generation Clear + Brilliant laser. By seamlessly switching between two wavelengths with the Original and Perméa handpieces, physicians can now more easily deliver a
- And The Winner Is... Algeness Named Top Finalist in Terra2 Solution Skin Health Innovation Competitionhttps://modernaesthetics.com/news/and-the-winner-is-algeness-named-top-finalist-in-terra2-solution-skin-health-innovation-competition/2473067/Advanced Aesthetic Technologies, Inc. (AAT) and Algeness are finalists in the recent Terra2 Solutions Skin Health Innovation Competition. Algeness is a patented family of fully resorbable injectable gel implant dermal fillers that are 100% natural and based on purified agarose with
- Pre-clinical Data Suggest Soliton's RAP Technology Can Help Liver Fibrosishttps://modernaesthetics.com/news/pre-clinical-data-suggest-solitons-rap-technology-can-help-liver-fibrosis/2473066/A pre-clinical study in animals demonstrates positive results for Soliton’s RAP device as a potential treatment for liver fibrosis. Validated laboratory and histological assessments in a mouse model demonstrated that Rapid Acoustic Pulse (RAP) therapy reduced the effects of induced liver fi
- Introducing the Cutaneous Procedures Adverse Events Reporting (CAPER) Systemhttps://modernaesthetics.com/news/introducing-the-cutaneous-procedures-adverse-events-reporting-caper-system/2473065/The American Society for Dermatologic Surgery Association (ASDSA) and the Northwestern University Department of Dermatology are launching the Cutaneous Procedures Adverse Events Reporting (CAPER) system. This voluntary reporting system gathers patients’ adverse events (AEs) encoun
- It’s Settled: AbbVie and Evolus Come to Agreementhttps://modernaesthetics.com/news/its-settled-abbvie-and-evolus-come-to-agreement/2473064/AbbVie, Evolus, and Medytox have agreed to new settlement agreements to fully resolve all outstanding litigation, including the US International Trade Commission (ITC) case regarding the sale of Jeuveau®, between the companies. A California court case filed by Medytox against Evolus
- Industry Responds to COVID-19: Biopelle, Galderma US Aestheticshttps://modernaesthetics.com/news/industry-responds-to-covid-19-biopelle-galderma-us-aesthetics/2473063/Biopelle One bright spot for many aesthetic practices during the COVID-19 pandemic has been persistent and perhaps increased demand for skincare. Biopelle has responded to support physicians who wish to dispense their products. “We offer a ski
- Evolus’ Jeuveau Can Stay on U.S. Market For Nowhttps://modernaesthetics.com/news/evolus-jeuveau-gets-stay-of-execution/2473061/Evolus Inc. can remain for sale in the U.S. temporarily while an appeals court re-considers an import ban won by AbbVie Inc.’s Allergan that was slated to go into effect on Feb. 16, 2021, according to
- Pulse Biosciences Gets FDA Clearance for CellFXhttps://modernaesthetics.com/news/pulse-biosciences-gets-fda-clearance-for-cellfx/2473058/The FDA has cleared the CellFX® System from Pulse Biosciences, Inc. for dermatologic procedures requiring ablation and resurfacing of the skin, and a controlled commercial launch will soon beginning in the US with a of select group of leaders in aesthetic dermatology. The
- Soliton’s RAP Technology Cleared for Cellulitehttps://modernaesthetics.com/news/solitons-rap-technology-cleared-for-cellulite/2473057/The FDA has cleared Soliton Inc.’s Rapid Acoustic Pulse (RAP) technology for the short-term improvement in the appearance of cellulite. Harnessing the power of sound, the unique, rapid-pulsed technology safely and comfortably breaks apart the fibrous septa bands beneath the skin that cause
- FDA Greenlights Galderma's Restylane Defyne for Chin Augmentationhttps://modernaesthetics.com/news/fda-greenlights-galdermas-restylane-defyne-for-chin-augmentation/2473055/The U.S. Food and Drug Administration (FDA) has approved Restylane Defyne for the augmentation and correction of mild to moderate chin retrusion in adults over the age of 21. Restylane Defyne is a hyaluronic acid (HA) dermal filler that was first approved in 201